Targeted therapies have transformed treatment of driver-mutated metastatic NSCLC. We compared cardiovascular adverse events between and within targeted therapy classes. READ ARTICLE
Journal of Thoracic Oncology
DOI:10.1016/j.jtho.2021.07.030
Authors: Sarah Waliany, Han Zhu, Heather Wakelee, Sukhmani K. Padda, Millie Das, Kavitha Ramchandran, Nathaniel J. Myall, Thomas Chen, MD, Ronald M. Witteles, Joel W. Neal